 Oncolytics Biotech Inc. NASDAQ: ONCY TSX: ONC, currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced the publication of an electronic-poster ePoster with clinical proof-of-concept data from the Companys phase 1b study in carfilzomib-refractory multiple myeloma patients treated with pelareorep in combination with carfilzomib Kyprolis. Data presented in the ePoster demonstrates that the pelareorep-carfilzomib combination treatment results in selective replication of pelareorep in cancer cells and beneficial induction of an inflamed tumor environment associated with clinical responses. The ePoster was published this morning and will be presented this weekend as part of the American Society of Clinical Oncology ASCO Virtual Annual Meeting. 